Comparing the current results to its competitors, Arbutus Biopharma reported Revenue increase in the 1 quarter 2026 by 10054.54 % year on year. The sales growth was above Arbutus Biopharma's competitors' average revenue growth of 14.25 %, achieved in the same quarter.
Arbutus Biopharma's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes established global pharmaceutical firms, research-stage companies, academic and research institutions, and government agencies involved in the discovery, development, and commercialization of novel therapeutics for treating HBV. Many competitors possess greater financial, product development, technical, manufacturing, sales, and marketing resources. Direct competitors often consist of large pharmaceutical companies with internal research and development capabilities experienced in product testing, regulatory approvals, and market acceptance. Specific competitors identified include GSK plc, Gilead Sciences, Inc., Assembly Biosciences, Inc., and Aligos Therapeutics, Inc. The company expects to face competition from new products entering the market that may be safer, more effective, or better marketed, which could impact the competitiveness of its product candidates.
Due to outstanding performance in Overall company, revenue grew by 10054.54 % Arbutus Biopharma Corp improved its market share, to approximately 0.2 %.
November 26, 2024
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company renowned for its innovative approaches to virology, has announced its participation in the H.C. Wainwright @ Home virtual fireside chat series scheduled for December 3, 2024, at 11:00 AM ET. This engagement is anticipated to be a significant opportunity for the company to share insights into its ongoing developments and strategy focused on addressing chronic hepatitis B virus (cHBV) infection.Hepatitis B remains a pervasive global health challenge, affecting millions worldwide. Recognising the urgent need for effective treatments, Arbutus Biopharma is dedicated to leveraging its extensive expertise in virology to develop...
April 4, 2024
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company specializing in virology, has recently announced a significant development in its ongoing patent infringement lawsuit against Moderna, Inc. In collaboration with its licensee Genevant Sciences, Arbutus seeks damages for the alleged infringement of several U.S. patents in the manufacture and sale of Moderna s COVID-19 vaccine, MRNA-1273. The U.S. District Court for the District of Delaware has issued a claim construction ruling, which will have significant implications for the future of this lawsuit.Background:Arbutus Biopharma is committed to developing a functional cure for individuals with chronic hepatitis B virus (cHBV) infection. ...
Xbiotech Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic antibodies. They seek to address unmet medical needs by leveraging their proprietary True Human antibody technology.
Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines. They aim to leverage their proprietary recombinant nanoparticle vaccine technology platform to address a wide range of infectious diseases. By collaborating with partners and conducting clinical trials, Novavax works towards bringing innovative vaccines to the global market.
Matinas Biopharma Holdings Inc operates as a clinical-stage biopharmaceutical company. Their business model centers around developing therapeutics through the utilization of lipid nano-crystal (LNC) platform technologies. These technologies enable the effective delivery of drugs to improve patient outcomes in various diseases and conditions such as fungal infections, viral infections, and cancer.
Sources:
Arbutus Biopharma Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Arbutus Biopharma Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
